Literature DB >> 22810810

The rationale for targeting the LOX family in cancer.

Holly E Barker1, Thomas R Cox, Janine T Erler.   

Abstract

The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22810810     DOI： 10.1038/nrc3319

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  171 in total

Review 1.  Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell.

Authors:  Herbert M Kagan; Wande Li
Journal:  J Cell Biochem       Date:  2003-03-01       Impact factor: 4.429

2.  Systematic variation in gene expression patterns in human cancer cell lines.

Authors:  D T Ross; U Scherf; M B Eisen; C M Perou; C Rees; P Spellman; V Iyer; S S Jeffrey; M Van de Rijn; M Waltham; A Pergamenschikov; J C Lee; D Lashkari; D Shalon; T G Myers; J N Weinstein; D Botstein; P O Brown
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

Review 3.  Tissue cells feel and respond to the stiffness of their substrate.

Authors:  Dennis E Discher; Paul Janmey; Yu-Li Wang
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

4.  Induction of cardiac fibroblast lysyl oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling.

Authors:  Tetyana G Voloshenyuk; Elizabeth S Landesman; Elena Khoutorova; Andrew D Hart; Jason D Gardner
Journal:  Cytokine       Date:  2011-04-17       Impact factor: 3.861

5.  The potential for LOXL2 as a target for future cancer treatment.

Authors:  Holly E Barker; Janine T Erler
Journal:  Future Oncol       Date:  2011-06       Impact factor: 3.404

6.  Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.

Authors:  Stacey L Payne; Ben Fogelgren; Angela R Hess; Elisabeth A Seftor; Elizabeth L Wiley; Sheri F T Fong; Katalin Csiszar; Mary J C Hendrix; Dawn A Kirschmann
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.

Authors:  Francesca Pasutto; Mandy Krumbiegel; Christian Y Mardin; Daniela Paoli; Robert Lämmer; Bernhard H F Weber; Friedrich E Kruse; Ursula Schlötzer-Schrehardt; André Reis
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

8.  Systematic screening of lysyl oxidase-like (LOXL) family genes demonstrates that LOXL2 is a susceptibility gene to intracranial aneurysms.

Authors:  Hiroyuki Akagawa; Akira Narita; Haruhiko Yamada; Atsushi Tajima; Boris Krischek; Hidetoshi Kasuya; Tomokatsu Hori; Motoo Kubota; Naokatsu Saeki; Akira Hata; Tohru Mizutani; Ituro Inoue
Journal:  Hum Genet       Date:  2007-02-08       Impact factor: 4.132

9.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.

Authors:  Debra F Higgins; Kuniko Kimura; Wanja M Bernhardt; Nikita Shrimanker; Yasuhiro Akai; Bernd Hohenstein; Yoshihiko Saito; Randall S Johnson; Matthias Kretzler; Clemens D Cohen; Kai-Uwe Eckardt; Masayuki Iwano; Volker H Haase
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Evaluation of LOXL1 polymorphisms in exfoliation syndrome in a Chinese population.

Authors:  Ling Chen; Liyun Jia; Ningli Wang; Guangxian Tang; Chun Zhang; Sujie Fan; Wenru Liu; Hailin Meng; Wotan Zeng; Ningpu Liu; Huaizhou Wang; Hongyan Jia
Journal:  Mol Vis       Date:  2009-11-14       Impact factor: 2.367
View more
  221 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide.

Authors:  Gokhan Baris Ozdener; Manish V Bais; Philip C Trackman
Journal:  Mol Oncol       Date:  2015-08-06       Impact factor: 6.603

3.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

4.  Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma.

Authors:  Yulong Chen; Masahiko Terajima; Yanan Yang; Li Sun; Young-Ho Ahn; Daniela Pankova; Daniel S Puperi; Takeshi Watanabe; Min P Kim; Shanda H Blackmon; Jaime Rodriguez; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Rosalba Minelli; Kenneth L Scott; Johannah Sanchez-Adams; Farshid Guilak; Debananda Pati; Nishan Thilaganathan; Alan R Burns; Chad J Creighton; Elisabeth D Martinez; Tomasz Zal; K Jane Grande-Allen; Mitsuo Yamauchi; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

5.  Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.

Authors:  Kathy A Toy; Rajeshwari R Valiathan; Fernando Núñez; Kelley M Kidwell; Maria E Gonzalez; Rafael Fridman; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2015-02-10       Impact factor: 4.872

6.  Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.

Authors:  Fernando Salvador; Alberto Martin; Celia López-Menéndez; Gema Moreno-Bueno; Vanesa Santos; Alberto Vázquez-Naharro; Patricia G Santamaria; Saleta Morales; Pierre R Dubus; Laura Muinelo-Romay; Rafael López-López; Jason C Tung; Valerie M Weaver; Francisco Portillo; Amparo Cano
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

7.  Proteolytic processing of lysyl oxidase-like-2 in the extracellular matrix is required for crosslinking of basement membrane collagen IV.

Authors:  Alberto J López-Jiménez; Trayambak Basak; Roberto M Vanacore
Journal:  J Biol Chem       Date:  2017-09-01       Impact factor: 5.157

8.  LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Authors:  Shizhen Zhu; Xiaoling Zhang; Nina Weichert-Leahey; Zhiwei Dong; Cheng Zhang; Gonzalo Lopez; Ting Tao; Shuning He; Andrew C Wood; Derek Oldridge; Choong Yong Ung; Janine H van Ree; Amish Khan; Brittany M Salazar; Edroaldo Lummertz da Rocha; Mark W Zimmerman; Feng Guo; Hong Cao; Xiaonan Hou; S John Weroha; Antonio R Perez-Atayde; Donna S Neuberg; Alexander Meves; Mark A McNiven; Jan M van Deursen; Hu Li; John M Maris; A Thomas Look
Journal:  Cancer Cell       Date:  2017-08-31       Impact factor: 31.743

9.  A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.

Authors:  Dong-Joo Cheon; Yunguang Tong; Myung-Shin Sim; Judy Dering; Dror Berel; Xiaojiang Cui; Jenny Lester; Jessica A Beach; Mourad Tighiouart; Ann E Walts; Beth Y Karlan; Sandra Orsulic
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

10.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.